NCT01546649已完成3 期
A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer
Takeda0 个研究点目标入组 167 人开始时间: 2012年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 167
- 主要终点
- Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=<30 pg/mL) From Week 4 Through Week 48
研究概览
简要总结
Hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) will be evaluated against TAP-144-SR(3M) in postoperative and hormone therapy-naïve patients with premenopausal breast cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The participant has histopathologically-confirmed primary breast cancer in Japanese.
- •The participant is aged 20 years or older when informed consent is obtained
- •The participant has estrogen receptor (ER)-positive tumor cells and/or progesterone receptor (PgR)-positive primary tumor. And HER-2 is negative.
- •The participant has breast cancer in the clinical stages of T1-T3, N-any and M0 by TNM classification (the seventh edition, proposed by UICC in 2009). (No distant metastasis to lung, liver and bone should be confirmed on the image-based diagnosis at study enrollment. The image taken within 12 weeks prior to study enrollment is also available for the diagnosis.) The number of axillary lymph node metastasis is not limited.
- •Any operative procedure for breast cancer is acceptable. In principle, after breast-conserving surgery, the participant will receive postoperative radiation to the conserving breast.
- •Neoadjuvant chemotherapy and adjuvant chemotherapy prior to study enrollment are acceptable. (It is advisable the same kind of chemotherapy is performed at each site.)
- •The participant has a history of regular menstrual periods within 12 weeks prior to study enrollment, or the participant has FSH of less than 40 mIU/mL and E2 of 10 pg/mL or more measured within 12 weeks prior to study enrollment. The participant has not had a chemical menopause (i.e., FSH of less than 40 mIU/mL and E2 of 10 pg/mL or more) within 12 weeks after completing adjuvant chemotherapy.
- •The participant is in a condition to receive study drug and Tamoxifen (TAM) within 12 weeks after surgery or after adjuvant chemotherapy prior to study enrollment. Adjuvant chemotherapy prior to study is required to have been completed at the time of study enrollment.
- •The participant has ECOG performance status of grades 0 or 1 at the time of study enrollment.
- •The participant meets the following criteria of hepatic, renal and bone marrow functions on the laboratory test results at screening:
- •Hepatic function: AST (GOT) ≤ 3.0 times the upper limit of normal (ULN) ALT (GPT) ≤ 3.0 times the ULN
- •Renal function: serum creatinine level < 1.5 times the ULN
- •Bone marrow function : white blood cell count ≥ 3,000/mm3 platelet count ≥ 100,000/μL hemoglobin ≥ 10.0g/dL
- •The participant agrees to use a non-hormonal method of contraception through the study period.
排除标准
- •The participant has received neoadjuvant or adjuvant hormonal therapy for the latest breast cancer surgery.
- •The participant has received bilateral oophorectomy and bilateral ovarian irradiation.
- •The participant has inflammatory breast cancer or bilateral breast cancer.
- •The participant has non-invasive ductal carcinoma.
- •The participant has multiple primary cancers, or a history of carcinoma in other organs.
- •The participant is pregnant or breast-feeding.
- •The participant has a history of hypersensitivity to synthetic LH-RH, LH-RH derivative, TAM, TAM analogue (antiestrogen) or any component of the study drug.
- •The participant has a history of, or has been diagnosed with thromboembolism including myocardial infarction, cerebral infarction, venous thrombosis, and pulmonary embolism, or cardiac failure.
- •Patients whose QTcF interval exceeded 460 msec on the 12-lead electrocardiogram at screening.
研究组 & 干预措施
TAP-144-SR(6M)
Experimental
TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks.
干预措施: TAP-144-SR(6M) (Drug)
TAP-144-SR(3M)
Active Comparator
TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks.
干预措施: TAP-144-SR(3M) (Drug)
结局指标
主要结局
Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=<30 pg/mL) From Week 4 Through Week 48
时间窗: Week 4 up to Week 48
Comparison of both the treatment groups was done by assessing the suppressive effect on serum E2 concentration maintained at menopausal level (=\<30pg/mL). Suppression rate was calculated as proportion of participants maintained at menopausal level.
次要结局
- Disease Free Survival (DFS) Rate at Week 96(Week 96)
- Distant Disease Free Survival (DDFS) Rate at Week 96(Week 96)
- Serum Unchanged TAP-144 Level(Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309 and 337)
- Concentration of Serum Luteinizing Hormone (LH)(Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673)
- Concentration of Serum E2(Baseline, Hour (hr) 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673)
- Concentration of Follicle Stimulating Hormone (FSH)(Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673)
- QT Interval Measured by 12-lead Electrocardiogram (ECG)(Baseline, Hour 1, 3, 6 on Day 1, Day 29, 85, 169 and 337)
研究者
相似试验
已完成
3 期
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal TherapyProstate CancerNCT01546623Takeda160
进行中（未招募）
3 期
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of AgeCystic FibrosisNCT05422222Vertex Pharmaceuticals Incorporated210
已完成
3 期
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 YearsCystic FibrosisNCT04537793Vertex Pharmaceuticals Incorporated83
已完成
3 期
A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RARheumatoid ArthritisNCT03147248Celltrion407
终止
3 期
Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of AgeCystic FibrosisNCT03633526Vertex Pharmaceuticals Incorporated18